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Background: Foamy macrophages, containing myelin degradation products, are abundantly found in active
multiple sclerosis (MS) lesions. Recent studies have described an altered phenotype of macrophages after myelin
internalization. However, mechanisms by which myelin affects the phenotype of macrophages and how this
phenotype influences lesion progression remain unclear.
Results: We demonstrate that myelin as well as phosphatidylserine (PS), a phospholipid found in myelin, reduce
nitric oxide production by macrophages through activation of peroxisome proliferator-activated receptor β/δ
(PPARβ/δ). Furthermore, uptake of PS by macrophages, after intravenous injection of PS-containing liposomes
(PSLs), suppresses the production of inflammatory mediators and ameliorates experimental autoimmune
encephalomyelitis (EAE), an animal model of MS. The protective effect of PSLs in EAE animals is associated with a
reduced immune cell infiltration into the central nervous system and decreased splenic cognate antigen specific
proliferation. Interestingly, PPARβ/δ is activated in foamy macrophages in active MS lesions, indicating that myelin
also activates PPARβ/δ in macrophages in the human brain.
Conclusion: Our data show that myelin modulates the phenotype of macrophages by PPAR activation, which may
subsequently dampen MS lesion progression. Moreover, our results suggest that myelin-derived PS mediates
PPARβ/δ activation in macrophages after myelin uptake. The immunoregulatory impact of naturally-occurring
myelin lipids may hold promise for future MS therapeutics.
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Multiple sclerosis (MS) is characterized by central ner-
vous system (CNS) infiltration of activated myelin-
reactive lymphocytes and macrophages. Microglia and
macrophages typically accumulate in the perivascular
spaces and the brain parenchyma near terminal ovoids
of transected axons [1]. Effector mechanisms of activated
macrophages and microglia include internalization of
myelin and secretion of inflammatory and toxic media-
tors, which negatively influence axonal and myelin integ-
rity [2-7].
Macrophages are able to adopt divergent phenotypes
depending on environmental cues [8-10]. In MS, macro-
phages and microglia initially display a pro-inflammatory* Correspondence: Jerome.Hendriks@uhasselt.be
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reproduction in any medium, provided the orphenotype [5-7,11]. However, upon internalization of
myelin, they have been described to obtain anti-
inflammatory characteristics [12-17]. We have previously
demonstrated that myelin-derived cholesterol plays a
role in directing this typical phenotype of myelin-
phagocytosing macrophages by activating the sterol
sensing liver-X-receptors (LXRs) [13]. Nonetheless, not
all myelin-mediated effects on macrophages were in-
duced by LXRs and cholesterol, and it is therefore likely
that other myelin components also affect the phenotype
of myelin-phagocytosing macrophages.
Phosphatidylserine (PS) is a phospholipid abundantly
found in myelin [18]. One of the hallmarks of apoptosis
is the translocation of PS to the outer membrane leaflet,
where it serves as an “eat me” signal for phagocytic
clearance [19,20]. Apoptotic cell clearance via PS skews
macrophages and microglia towards an anti-inflammatory
phenotype, similar to myelin-phagocytosing macrophages,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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stasis [21-24]. Since clearance of apoptotic cells by expos-
ure of PS to macrophages and the subsequent induction
of a tolerogenic phenotype has been associated with per-
oxisome proliferator-activated receptor (PPAR) activation
[25], we determined whether a myelin-mediated PPAR
activation is involved in directing the phenotype of macro-
phages during immune-mediated demyelination. Further-
more, we assessed the impact of PS-containing liposomes
(PSLs) on neuroinflammation. We demonstrate that mye-
lin as well as PS suppress the production of the inflamma-
tory mediator nitric oxide (NO) by macrophages through
activation of PPARβ/δ. Importantly, we provide compel-
ling evidence that PSLs are immunosuppressive in an
experimental MS animal model and that PPARβ/δ respon-
sive genes and their corresponding proteins are markedly
upregulated in myelin-phagocytosing macrophages in
active demyelinating MS lesions. Taken together, our find-
ings indicate that a myelin-mediated PPAR activation in
macrophages may affect lesion progression in demyelinat-
ing diseases such as MS.Figure 1 Myelin and PSLs modulates the macrophages phenotype by
supernatants of LPS stimulated control, myelin- or PSL-treated macrophage
antagonists for PPARα (GW6471), PPARβ/δ (GSK0660) or PPARγ (GW9662). T
in experimental cultures divided by values in stimulated control cultures. D
control cultures in which no antagonists were added.Results
Myelin and PS modulate the macrophages phenotype by
activating PPARs
To assess whether myelin affects the inflammatory
phenotype of macrophages through activation of PPARα,
β/δ or γ, macrophages were treated for 2 h with specific
antagonists for PPARα (GW6471), β/δ (GSK0660) and γ
(GW9662), prior to administration of myelin. While
PPARα or PPARγ antagonists did not influence the
reduced production of the inflammatory mediator NO
by myelin-phagocytosing macrophages, a PPARβ/δ se-
lective antagonist counteracted the decline in NO
production (Figure 1a). The decrease in IL-6 production
by myelin-phagocytosing macrophages was not affected
by the antagonists (Figure 1b). This is in accordance
with our previous study in which we demonstrated that
suppression of IL-6 production by macrophages upon
myelin internalization is LXRβ dependent. Notably,
although macrophages expressed all PPAR subtypes,
PPARβ/δ showed the highest expression (Additional
file 1: Figure S1a).PPARβ/δ activation. (a-c) Relative NO and IL-6 concentration in
s. Prior to administration of myelin or PSLs, cells were treated with
he relative NO and IL-6 production is defined as the production of NO
ata represent the mean ± SEM of five independent experiments. (−):
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the phenotype of macrophages upon myelin uptake,
macrophages were incubated with PSLs and non-PS
-containing liposomes (PCLs). PSLs have been described
to mimic the functional effects of apoptotic cell clear-
ance by macrophages [19,23]. First, the abundance of PS
in isolated myelin was determined and compared to that
in PSLs and PCLs. Flow cytometric analysis demon-
strated that isolated myelin and PSLs contained similar
levels of PS (Additional file 1: Figure S1b). Subsequently,
the capacity of macrophages to internalize liposomes
was determined. Like DiI-labeled myelin [12], both
DiI-labeled PSLs and PCLs were internalized efficiently
by macrophages in vitro (Additional file 1: Figure S1c).
Finally, we assessed whether PS uptake affects the pro-
duction of NO by macrophages through activation of
PPARβ/δ. Similar to myelin-phagocytosing macrophages,
the PPARβ/δ selective antagonist counteracted the re-
duced secretion of NO by PSL-treated macrophagesFigure 2 Systemically administered liposomes home primarily to sple
were injected with 5 mg/kg DiI-labeled PCLs and PSLs. Splenic cryosection
zone macrophages) and CD68 (b, red pulp macrophages). One representat(Figure 1c). In contrast to PSLs, PCLs did not alter NO
production by macrophages (Additional file 1: Figure
S1d). Of note, the PPARβ/δ antagonist did not affect the
capacity of macrophages to internalize myelin or lipo-
somes (Additional file 1: Figure S1e-g), indicating that a
reduced internalization of myelin and liposomes does
not account for the increase in NO production following
administration of the PPARβ/δ antagonist. These results
show that myelin modulates the inflammatory pheno-
type of macrophages by activating PPARβ/δ and suggest
that PS in myelin is responsible for this activation.
Systemically administered liposomes home primarily to
splenic macrophages and ameliorate EAE
To determine if PS uptake by macrophages influences
the pathology and severity of experimental autoimmune
encephalomyelitis (EAE), immunized rats were treated
with PBS, PCLs or PSLs. First, the homing properties
of liposomes after intravenous administration ofnic marginal zone and red pulp macrophages. (a,b) Healthy rats
s were stained with CD169 (a, marginal metallophilic and marginal
ive experiment is shown (20× magnification).
Figure 3 Intravenously injected PSLs reduce CNS infiltration of immune cells and ameliorate EAE. (a) MOG-immunized animals were
treated daily with PBS (n=8; black), 5 mg/kg PCLs (n=8; dark grey) or 5 mg/kg PSLs (n=8; light grey) starting from day 5. Neurological score and
weight were assessed daily. Data represent the mean ± SEM. *P < 0.05 (vehicle vs PSL), +P < 0.05 (PCL vs. PSL). (b) Spinal cord tissue was isolated
30 dpi and stained with CD3 (20× magnification) and CD68 (4× magnification). One representative image is shown. (c,d) Quantification of T cell
and macrophage infiltration in spinal cord tissue 30 dpi. Nine cryosections, covering the complete length of the spinal cord, were stained with
CD68 (c) and CD3 (d). A 4× magnification was used to determine the amount of immune cell infiltration. Data represent the mean ± SEM of
4 animals.
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and immunohistochemistry. In healthy animals, injected
PSLs were primarily retrieved in the spleen and liver
(Additional file 2: Figure S2a). Furthermore, immunohis-
tochemical analysis demonstrated that especially splenicCD169+ marginal zone and CD68+ red pulp macro-
phages contained liposomes (Figure 2a and b). The
absence of liposomes in CNS tissue suggests that
liposomes are incapable of crossing an intact blood–
brain-barrier. Similar to healthy animals, PSLs homed
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EAE onset (Additional file 2: Figure S2b). However, in
these immunized animals we were also able to detect
sporadic CD68+ macrophages in the spinal cord
containing DiI-liposomes (Additional file 2: Figure S2c).
The high number of liposomes present in the lungs may
be explained by the fact that they are trapped in the nar-
row capillaries of the lung. Collectively, these results
show that PSLs migrate towards splenic red pulp and
marginal zone macrophages after systemic administra-
tion, but can also enter the CNS during EAE. Whether
liposomes are phagocytosed by systemic macrophages
that subsequently enter the CNS or freely cross the
compromised blood–brain-barrier remains to be clarified.
To assess the effect of PSLs on EAE development, im-
munized animals were treated daily with PSLs, PCLs or
PBS, starting 5 days post-immunization (dpi). PSL-
treated animals displayed a significantly reduced neuro-
logical score compared to PCL- (area under the curve
(AUC), PSL: 7.41 ± 4.38 vs PCL: 30.13 ± 6.11, P < 0.05,
Figure 3a) and vehicle-treated animals (AUC, PSL: 7.41
± 4.38 vs vehicle: 34.53 ± 10.80, P < 0.05, Figure 3a).
Furthermore, disease incidence was lower in animals
treated with PSLs (62.5%), compared to PCL- (100%)
and vehicle-treated animals (87.5%). The reduced disease
severity in PSL-treated animals was paralleled with
decreased numbers of CNS infiltrating macrophages and
T cells (Figure 3b-d). Although PCL treatment did not
significantly affect disease severity, PCL-treated animals
did have significantly reduced numbers of infiltrated
immune cells in the CNS, as compared to vehicle treated
animals.
To determine the therapeutic potential of PSLs, EAE
animals were treated daily with PSLs or PBS, starting
one day after disease onset. Similar as in the prophylac-
tic regimen, PSL-treated animals displayed a significantly
reduced neurological score compared to vehicle-treated
animals (AUC, PSL: 17.5 ± 5.21 vs vehicle: 34.25 ± 3.53,
P < 0.05, Figure 4). Collectively, these data show that
PSLs attenuate the course of EAE when administered
both before and after disease onset.Figure 4 PSLs have a therapeutic effect on EAE. MOG-immunized anim
grey) starting at disease onset. Neurological score and weight was assessedPSLs modulate T cell proliferation and the expression of
pro- and anti-inflammatory mediators in the spleen
To determine the impact of PSLs on T cell proliferation,
cognate antigen specific proliferation of splenic cultures
from vehicle-, PCL- and PSL-treated animals was assessed.
Splenic T cells from PSL-treated animals showed a signifi-
cantly reduced myelin oligodendrocyte glycoprotein
(MOG) reactivity, compared to both vehicle- and PCL-
treated animals (Figure 5a). In line with this, the mean
white pulp surface area in the spleen, determined by
measuring the marginal metallophilic macrophages-
surrounded area, was reduced in animals treated with
PSLs (Figure 5b). Representative images of these measure-
ments are depicted in Additional file 3: Figure S3a. No dif-
ferences in splenic gene expression of transcription factors
characteristic for divergent T cell subsets, such as T-bet
(Th1), GATA-3 (Th2), RORγt (Th17) and Foxp3 (Treg),
were detected (Additional file 3: Figure S3b).
To further determine the underlying mechanisms by
which PSLs modulate EAE pathogenesis, splenic expres-
sion of inducible nitric oxide synthase (iNOS), TNFα
and arginase-1 (ARG-1) was assessed. Whereas iNOS
and TNFα are typical inflammatory mediators produced
by macrophages, ARG-1 is a commonly used marker for
alternatively activated macrophages. Reduced iNOS and
TNFα mRNA levels were observed in spleens of PSL-
treated animals (Figure 5c and d). Furthermore, although
splenic ARG-1 mRNA expression was unaffected, the
total fluorescent intensity of splenic ARG-1 expression
was significantly increased in animals treated with PSLs,
indicating enhanced arginase activity (Figure 5e). Repre-
sentative images of these measurements are depicted in
Additional file 3: Figure S3c. The altered expression of
iNOS, TNFα and ARG-1 in PSL-treated animals is in
agreement with the ability of PSLs to affect the
expression of these mediators by macrophages in vitro
(Figure 1c, Additional file 3: Figure S3d and S3e).
These results demonstrate that PSL treatment sup-
presses T cell proliferation without affecting their
polarization. Furthermore, we show that PSLs affect the
expression of iNOS, TNFα and ARG-1 in vivo in aals were treated daily with PBS (n=6; black) or 5 mg/kg PSLs (n=6; light
daily. Data represent the mean ± SEM.
Figure 5 PSLs affect splenic cognate antigen specific proliferation and expression of TNFα, iNOS and ARG-1. (a) Cognate antigen specific
proliferation (10 dpi) of splenic cultures was assessed by culturing splenic cells from vehicle, PCL and PSL treated animals with MOG. Proliferation
was assessed by [3H]thymidine incorporation. Non-stimulated cultures were used as control (dotted line). Data represent the mean ± SEM of four
experiments. (b) The size of the splenic white pulp was determined using ImageJ software. Three cryosections per animal were stained with
CD200R, a marker for myeloid cells, after which the surface area surrounded by the marginal metallophilic macrophages was determined. Five
images (4× magnification) per section were taken to calculate the mean white pulp size. Data represent the mean ± SEM of four animals. (c,d)
Comparison of fold changes between vehicle, PCL and PSL-treated spleens 10 dpi. Relative quantification of iNOS (c) and TNFα (d) was accompli-
shed by using the comparative Ct method. Data were normalized to the most stable reference genes, determined by Genorm (Pgk1 and Rpl13a).
Data represent the mean ± SEM of 4 experiments. (e) Spleen cryosections were stained with ARG-1 after which the total corrected fluorescence
was determined using ImageJ software, as described previously [65]. Three cryosections were stained and 6 images (10× magnification) were
taken per section. Data represent the mean ± SEM of four animals.
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These immunosuppressive and anti-inflammatory proper-
ties of PSLs likely contribute to the observed reduction in
neuroinflammation after PSL treatment.
Myelin-phagocytosing macrophages display increased
activation of PPARs in active MS lesions
To elucidate whether PPARs are also active in myelin-
containing macrophages in MS lesions, we determined
PPARβ/δ activation in MS CNS tissue by quantitative
PCR and immunohistochemistry. The expression of
PPARβ/δ responsive genes adipose differentiation
related protein (ADRP), carnitine palmitoyltransferase I
(CPT1a) and pyruvate dehydrogenase kinase isozyme 4
(PDK4) was assessed [26-28]. RNA was isolated from re-
gions accommodating lipid-containing macrophages and
microglia, determined by Oil Red O staining. Expression
of ADRP and CTP1a mRNA was increased in active
MS lesions, compared to non-demented controls
(Figure 6a-c). To establish whether PPARβ/δ responsive
genes are induced in myelin-containing macrophages in
MS lesions, the expression of ADRP was determined by
immunohistochemistry. In agreement with the PCR data,
immunohistochemical analysis showed that ADRP washighly abundant in active MS lesions compared to the
surrounding normal-appearing white matter (Figure 6d
and e). Moreover, macrophages containing myelin were
intensely stained by anti-ADRP in active MS lesions
(Figure 6F). Semi-quantitative analysis demonstrated
that 60% of the HLA-DR+ macrophages co-expressed
ADRP. Furthermore, ADRP was exclusively expressed by
HLA-DR+ macrophages and >95% of ADRP+HLA-DR+
macrophages contained myelin. These data show that
myelin-phagocytosing macrophages in MS lesions have
active PPARβ/δ signaling.
Discussion
In this study we aimed to determine whether myelin di-
rects the inflammatory phenotype of macrophages by
PPAR activation and how this phenotype impacts lesion
progression in MS. We show that internalization of mye-
lin and PSLs inhibit NO production by macrophages
through activation of PPARβ/δ. Furthermore, we dem-
onstrate that PSLs, internalized by splenic macrophages,
significantly reduce clinical signs in an experimental MS
animal model by suppressing autoaggressive T cells, low-
ering the expression of inflammatory mediators and
inhibiting infiltration of immune cells into the CNS.
Figure 6 (See legend on next page.)
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Figure 6 PPARs are activated in myelin-phagocytosing macrophages during active MS. (a-c) Comparison of fold changes between non-
demented controls (n=5) and active MS lesions (n=5). Relative quantification of ADRP (a), PDK4 (b) and CTP1a (c) was accomplished by using the
comparative Ct method. Data were normalized to the most stable reference genes, determined by Genorm (YHWAZ and Rpl13a). (d,e) Normal-
appearing white matter (d) and an active MS lesion (e) stained for ADRP. One representative image is shown (20× magnification). (f) Active MS
lesion stained with HLA-DR (green top; left corner), ADRP (red; top right corner), PLP (magenta; bottom left corner) and DAPI (blue, bottom right
corner). One representative image is shown (40× magnification).
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sponding proteins were markedly increased in myelin-
containing macrophages during active demyelination in
MS. Collectively, these findings indicate that myelin mod-
ulates the inflammatory phenotype of macrophages by ac-
tivating PPARβ/δ and suggest that PS in myelin is
responsible for this activation. The myelin-mediated acti-
vation of PPARs in macrophages may dampen lesion pro-
gression and explain the relapse-remitting nature of MS.
Myelin contains various lipids that may modify the
functional properties of macrophages. Recently, we dem-
onstrated that myelin-derived cholesterol influences the
phenotype of macrophages through activation of LXRs.
While the suppressed IL-6 production by myelin-
phagocytosing macrophages was LXRβ dependent, the
observed reduction in NO production was unaffected in
LXR-deficient macrophages. PS is a constituent of mye-
lin and a potent regulator of inflammatory responses. In
vitro, clearance of apoptotic cells and PSLs skews macro-
phages towards a tolerogenic phenotype [21,23,29-35].
Likewise, myelin internalization induces an anti-
inflammatory, immunosuppressive phenotype in macro-
phages [12-17]. Here we show that both myelin and
PSLs lower NO production by macrophages. Moreover,
we demonstrate that PPARβ/δ activation underlies the
effect that PSLs and myelin have on the phenotype of
macrophages. The myelin-mediated activation of PPARβ/
δ corresponds with the fact that myelin-phagocytosing
macrophages have an upregulated expression of genes in-
volved in PPAR signalling [13]. Moreover, these findings
are in line with studies showing that PPARβ/δ is a tran-
scriptional sensor of apoptotic cells and that it regulates
the program of alternative activation in macrophages
[25,36-39]. Interestingly, in a carrageenan-induced mouse
paw edema model it has been shown that PSLs are cap-
able of suppressing inflammation in vivo by activating
PPARγ [40], indicating that PSLs can affect inflammation
via multiple PPAR subtypes.
We demonstrate that systemically administered PSLs,
primarily internalized by splenic CD68+ red pulp and
CD169+ marginal zone macrophages, suppress EAE in
both prophylactic and therapeutic settings. In line with
our findings, other studies demonstrated that adminis-
tration of non-encapsulated PS ameliorates EAE when
administered before or after disease onset [41,42]. In
these studies it was described that the beneficial effect ofPS was mediated by a direct effect of PS on
autoaggressive T cell responses. Similar, PSLs have been
described to modulate T cell differentiation and suppress
antigen-specific immune responses in vivo [22,43]. We
now provide evidence that PS not only affects T cell re-
sponses but also influences macrophage behavior. The
PS-mediated change of the macrophage phenotype will
contribute to the immunosuppressive capacity of PSLs.
In vivo, PSLs have been described to promote the reso-
lution of inflammation by modulating macrophage
function in a model for inflammatory bone loss and
myocardial infarction [31,33]. As ARG-1 activity sup-
presses antigen-specific T cell responses [44,45], the in-
creased splenic expression of ARG-1 in PSL-treated
animals may account for the observed inhibition of
splenic T cell proliferation in our model. In addition to
the immunosuppressive effects of PSLs, we observed a
marked reduction in the numbers of macrophages and T
cells infiltrating into the CNS of PSL-treated EAE ani-
mals. This indicates that PSLs influence immune cell
trafficking towards the CNS, in addition to or as a result
of modulating the macrophages phenotype or T cell pro-
liferation. In summary, results from our study indicate
that PSLs will affect neuroinflammation by modulating
the functional properties of macrophages.
Interestingly, we demonstrate that the expression of
PPARβ/δ responsive genes and proteins is upregulated
in active MS lesions, especially in myelin-phagocytosing
macrophages. All PPAR subtypes have been described to
regulate the differentiation of macrophages towards an
anti-inflammatory phenotype [36-39,46-48]. Moreover,
agonists for all PPARs reduce CNS inflammation and
demyelination in EAE [49-56]. The importance of
PPARβ/δ signaling in maintaining immune-homeostasis
and preventing systemic autoimmunity is illustrated by
the fact that macrophage-specific PPARβ/δ deficiency
delays clearance of apoptotic cells and increases auto-
antibody production [25]. Our finding that PPARβ/δ is
active in myelin-containing macrophages in active MS
lesions indicates that degraded myelin also activates
PPARβ/δ in macrophages in the human brain. This
myelin-mediated PPAR activation may affect lesion pro-
gression by inducing an anti-inflammatory environment
and by influencing the activity of infiltrating T cells.
Moreover, as PPARβ/δ activation enhances the internal-
ization of apoptotic cells [25], myelin-mediated PPARβ/δ
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inhibits oligodendrocyte precursor maturation and axonal
regeneration [57-60], thereby stimulating repair.
Conclusion
This report provides an interesting link between demye-
lination, lipid metabolism and macrophage-mediated in-
flammation. Our data indicate that myelin modulates
the inflammatory phenotype of macrophages by activat-
ing PPARβ/δ and suggests that PS in myelin is respon-
sible for this activation. Since PSLs ameliorate EAE and
PPARβ/δ is activated in myelin-phagocytosing macro-
phages in active MS lesions, we hypothesize that during
MS pathogenesis myelin uptake by macrophages induces
naturally-occurring regulatory mechanisms by PPAR acti-
vation. The identification of myelin-derived lipids capable
of dampening macrophage-mediated inflammation can
potentially explain the relapse-remitting nature of MS and
holds promise for future intervention strategies aimed at
reducing neuroinflammation in disorders like MS.
Methods
Animals
Female Dark Agouti rats, 8–10 weeks old, were purchased
from Harlan Netherlands B.V. (Horst, The Netherlands).
Animals were housed in the animal facility of the Biomed-
ical Research Institute of Hasselt University. Experiments
were conducted in accordance with institutional guide-
lines and approved by the Ethical Committee for Animal
Experiments of Hasselt University.
Myelin isolation
Myelin was purified from rat brain tissue by means of
density-gradient centrifugation, as described previously
[61]. Myelin protein concentration was determined by
using the BCA protein assay kit (Thermo Fisher Scien-
tific, Erembodegem, Belgium). LPS content was deter-
mined using the Chromogenic Limulus Amebocyte
Lysate assay kit (Genscript Incorporation, Aachen,
Germany). Isolated myelin contained a neglectable
amount of endotoxin (˂1.8×10-3 pg/μg myelin). Expres-
sion of phosphatidylserine on myelin, PSLs and PCLs
was determined by flow cytometry using FITC-labeled
Annexin V (Biolegend, Antwerpen, Belgium).
Preparation of liposomes
Liposomes were prepared as described previously [62].
In brief, nitrogen-dried lipid films containing various
phospholipids were suspended in PBS and sonicated
for 10 min on ice. The liposomes were composed of
either phosphatidylcholine (PC; Sigma-Aldrich, Bornem,
Belgium) only or a combination of PC and PS (Sigma-
Aldrich) at a molar ratio of 7:3. In some experiments,
liposomes were fluorescently labeled with 1,1”-diotadecyl-3,3,3’,3’,-tetramethylindocarbocyanide perchlo-
rate (DiI; Sigma-Aldrich). For this, liposomes were incu-
bated with DiI for 10 min at 37°C, after which liposomes
were centrifuged to remove non-encapsulated DiI. Flow
cytometry was used to assess labeling efficacy and the
degree of DiI-liposome uptake.
Cell culture
Rat macrophages (NR8383; ATCC, Molsheim, France)
were cultured in RPMI 1640 medium (Lonza, Vervier,
Belgium) enriched with 10% fetal calf serum (Hyclone,
Erenbodegen, Belgium), 50 U/ml penicillin and 50 U/ml
streptomycin (Invitrogen, Merelbeke, Belgium). Cells
were treated for 24 h with 100 μg/ml myelin, 250 μg/ml
PSLs or 250 μg/ml PCLs in 96-well plates (15 × 104
cells/well). Subsequently, cells were stimulated with 100
ng/ml LPS (Sigma-Aldrich) for 9 h for RNA isolation or
18 h for analysis of culture supernatants. To evaluate
the involvement of PPARs, macrophages were pretreated
for 2 h with antagonists for PPARα (GW6471,
10 μM, dissolved in DMSO), PPARβ/δ (GSK0660 10 μM,
dissolved in DMSO) and PPARγ (GW9662, 1 μM,
dissolved in DMSO) (all from Sigma-Aldrich). Cell viabil-
ity was determined using a 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide assay (MTT assay). In
short, following LPS stimulation the medium was
aspirated and replaced by medium supplemented with
12,5 μl sterile filtered MTT (Sigma-Aldrich). After 4h in-
cubation, the unreacted dye was aspirated and the insol-
uble formazan crystals were dissolved in 175 μl of a
DMSO – glycine solution. Absorbance was measured at
540–550 nm.
Nitrite formation and cytokine production
Culture supernatants of macrophages were collected
after 18 h stimulation with LPS. Release of NO was
determined using a Griess reagent system (Promega,
Leuven, Belgium). Cytokine concentrations in culture
supernatants were determined using a rat TNFα
(Ebioscience, Vienna, Austria) and rat IL-6 ELISA (R&D
systems, Abingdon, UK).
Induction of EAE and systemic liposome treatment
Rats were immunized subcutaneously at the base of the
tail with 140 μg of recombinant human MOG emulsified
in incomplete Freund’s adjuvant (Sigma-Aldrich) supple-
mented with 500 μg of heat-inactivated Mycobacterium
tuberculosis (Difco, Detroit, USA). Immunized animals
were treated daily with PBS, 5 mg/kg PCLs or 5 mg/kg
PSLs beginning 5 dpi or at disease onset. A total of 400
μl, containing liposomes or PBS, was injected intraven-
ously in the tail vein. In parallel, to track liposomes in
healthy and immunized animals, rats were injected with
5 mg/ml of DiI-labeled liposomes and sacrificed after
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according to the following neurological scale: 0.5 = par-
tial loss of tail tonus, 1 = complete loss of tail tonus,
2 = hind limb paresis, 3 = hind limb paralysis, 4 = mori-
bund, 5 = death.
[3H]Thymidine incorporation
Cognate antigen specific proliferation of T cells was de-
termined by measuring the amount of [3H]thymidine in-
corporation. In short, ficoll-separated splenic cells (20 ×
104, isolated 10 dpi) were cultured in RPMI 1640
medium supplemented with 50 U/ml penicillin, 50 U/ml
streptomycin, 20 μM 2-mercapto-ethanol (Sigma-Al-
drich), 1% sodium pyruvate (Invitrogen), 1% MEM
non-essential amino acids (Invitrogen), 2% deactivated
autologous serum and 20 μg/ml MOG. After 48 h, 1 μCi
[3H]thymidine (Amersham, Buckinghamshire, UK) was
added to the culture for 18 h. Next, cells were harvested
with an automatic cell harvester (Pharmacia, Uppsala,
Sweden) and radioactivity was measured in a β-plate
liquid scintillation counter (Wallac, Turku, Finland).
Quantitative PCR
Total RNA from cultures and tissues was prepared using
the RNeasy mini kit or RNeasy lipid tissue mini kit
(Qiagen, Venlo, The Netherlands), according to the
manufacturer’s instructions. The RNA concentration
and quality was determined with a NanoDrop spectro-
photometer (Isogen Life Science, IJsselstein, The
Netherlands). RNA was converted to cDNA using the
reverse transcription system (Promega) and quantitative
PCR was subsequently conducted on a StepOnePlus de-
tection system (Applied biosystems, Gaasbeek, Belgium),
as previously described [13]. Relative quantification of
gene expression was accomplished by using the com-
parative Ct method. Data were normalized to the most
stable reference genes [63,64]. Primers were chosen
according to literature or designed using Primer-Express
(http://www.ncbi.nlm.nih.gov/tools/primer-blast). Details
of the primers used are shown in Additional file 4: Table
S1 and clinical data of MS patients and non-neurological
controls (The Netherlands Brain Bank) are depicted in
Additional file 5: Table S2.
Immunohistochemistry
Animals were sacrificed in the effector (10 dpi) and
chronic phase (30 dpi) of EAE, after which brains, spinal
cords and spleens were isolated and snap-frozen. Frozen
brain material from MS patients and non-demented
controls was obtained from the Netherlands Brain Bank
(NBB, Amsterdam, Netherlands). Material was sectioned
with a Leica CM1900UV cryostat (Leica Microsystems,
Wetzlar, Germany) to obtain 7 μm slices. The extent of
immune cell infiltration in spinal cord sections wasdetermined using monoclonal mouse anti-rat CD68
(ED1 clone, AbD Serotec) and monoclonal mouse anti-
rat CD3 (1F4 clone, AbD Serotec). For tracking of
DiI-liposomes, spleen and spinal cord cryosections
were stained with anti-rat CD68 and monoclonal
mouse-anti-rat CD169 (ED3 clone, AbD serotec).
Additionally, splenic sections were stained with mono-
clonal mouse anti-Arginase 1 (19/Arginase I clone, BD
Biosciences, Erembodegem, Belgium) and polyclonal
goat anti-CD200R (M-21 clone, Santa Cruz, Heidelberg,
Germany). Human brain material was stained with
polyclonal rabbit anti-ADRP (Abcam, Cambridge, UK),
monoclonal mouse anti-HLA-DR (LN3 clone, eBio-
science) and polyclonal rabbit anti-PLP (Abcam). Alexa
fluor secondary antibodies were all purchased from
Invitrogen (Merelbeke, Belgium). In short, dried
cryosections were fixed in acetone for 10 minutes, after
which they were blocked for 30 minutes with 10% nor-
mal serum from the same species as the secondary anti-
body. Sections were incubated overnight with primary
antibodies, secondary antibodies were added for 2 h.
Nuclei were visualized using DAPI (Invitrogen). Control
stainings were performed by omitting the primary
antibody. PBS containing 0.05% Tween 20 (Merck,
Darmstadt, Germany) was used for washing and diluting
the antibodies. For 3, 3′ diaminobenzidine staining, the
Dako Envision+ kit (Dako) was used according to manu-
facturer’s instructions. Sections were counterstained with
hematoxylin (Merck, Darmstadt, Germany). Analysis was
carried out using a Nikon eclipse 80i microscope and NIS
Elements BR 3.10 software (Nikon, Tokyo, Japan).
Statistical analysis
Data were statistically analyzed using GraphPad Prism for
windows (version 4.03) and are reported as mean ± SEM.
D’Agostino and Pearson omnibus normality test was used
to test normal distribution. An ANOVA (post-hoc; Tukey)
or two-tailed unpaired Student t-test was used for nor-
mally distributed data sets. The Kruskal-Wallis (Dunns
post hoc comparison) or Mann–Whitney analysis was
used for data sets which did not pass normality. EAE
scores were analyzed using the Kruskal-Wallis (Dunns
post hoc comparison) and Mann–Whitney analysis. An
overall effect of treatment was assessed by measuring the
AUC. *P < 0.05, **P < 0.01 and ***P < 0.001.
Additional files
Additional file 1: Figure S1. Characteristics of macrophages, myelin,
liposomes and PPAR antagonists. (a) Comparison of PPARα, PPARβ/δ and
PPARγ mRNA expression in NR8383 cells. Relative quantification of PPARα,
β/δ and γ was accomplished by using the comparative Ct method. Data
were normalized to the most stable reference genes, determined by
Genorm (TBP and HMBS). Data represent the mean ± SEM of two
independent experiments. (b) Annexin V staining of myelin, PSLs and
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One representative experiment is shown (n=2). (c) Internalization of PSLs
and PCLs by macrophages. Macrophages were treated with DiI-labeled
PCLs (DiI-PCL) and PSLs (DiI-PSL) for 1.5 h. Liposome uptake was assessed
by flow cytometry. Data represent the mean ± SEM of two experiments.
(d) Relative NO concentration in supernatants of LPS stimulated control
and PCL-treated macrophages. The relative NO production is defined as
the production of NO in experimental cultures divided by values in
stimulated control cultures. Data represent the mean ± SEM of four
independent experiments. (e-g) Internalization of myelin and liposomes
by macrophages after pretreatment with PPAR antagonists. Macrophages
were treated for 2 h with antagonists for PPARα (GW6471), PPARβ/δ
(GSK0660) or PPARγ (GW9662) prior to administration of DiI-labeled
myelin (DiI-Myelin), PSLs (DiI-PSLs) and PCLs (DiI-PCLs) for 1.5 h. Uptake
was assessed by flow cytometry. The relative phagocytosis is defined as
the phagocytosis of myelin or liposomes in experimental cultures divided
by values in control conditions. Data represent the mean ± SEM of five
independent experiments. (−): control cultures in which no antagonists
were added.
Additional file 2: Figure S2. Homing properties of liposomes following
systemic administration. (a, b) Healthy (a) and immunized (b) rats were
injected with 5 mg/kg DiI-labeled PSLs. Immunized animals received
DiI-labeled liposomes one day after disease onset. After 24 h animals
were sacrificed and the homing properties of liposomes were assessed
by flow cytometry. To determine the homing of liposomes the amount
of DiI+ cells (cells which internalized liposomes) was divided by the total
number of organ cells analyzed. One representative experiment is shown
(n=2). (c) Immunized rats were injected with 5 mg/kg DiI-labeled PSLs
(DiI-PSL) at disease onset. After 24 h animals were sacrificed and spinal
cord cryosections were stained with CD68 (40× magnification). One
representative experiment is shown (n=3).
Additional file 3: Figure S3. Impact of liposomes on the inflammatory
properties of splenic tissue in EAE animals. (a) Spleen tissue was isolated
10 dpi and stained with CD200R (10× magnification). One representative
image is shown. WP: white pulp. (b) Comparison of fold changes
between vehicle, PCL and PSL-treated spleens 10 dpi. Relative
quantification of T-bet, GATA-3, RORγt and Foxp3 was accomplished by
using the comparative Ct method. Data were normalized to the most
stable reference genes, determined by Genorm (Pgk1 and Rpl13a). Data
represent the mean ± SEM of 4 animals. (c) Spleen tissue was isolated 10
dpi and stained with ARG-1 (10× magnification). An identical exposure
time and gain was used for all images. One representative image is
shown. (d) Relative TNFα concentration in supernatants of LPS stimulated
control and PSL-treated macrophages. The relative TNFα production is
defined as the production of TNFα in experimental cultures divided by
values in stimulated control cultures. Data represent the mean ± SEM of
five independent experiments. (e) Comparison of fold changes between
LPS stimulated control and PSL-treated macrophages. Relative
quantification of ARG-1 gene expression was accomplished by using the
comparative Ct method. Data were normalized to the most stable
reference genes, determined by Genorm (TBP and HMBS). Data represent
the mean ± SEM of three independent experiments.
Additional file 4: Table S1. Primer details.
Additional file 5: Table S2. Clinical data of MS patients and non-
neurological controls.
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